logo
Tick Bite? Here's What to Know About Lyme Disease and Your Next Steps

Tick Bite? Here's What to Know About Lyme Disease and Your Next Steps

CNET25-06-2025
You just finished a satisfying summer hike or wrapped up a weekend of yard work when you spot a tick clinging to your clothes. The fresh-air high fades quickly as you remember the risks -- ticks are known carriers of Lyme disease, a growing concern across the US.
Lyme disease cases have more than doubled in recent years, according to the CDC, with annual reports jumping from around 42,000 to nearly 90,000. While part of that increase is due to improved detection and reporting methods, the risk is still very real. Whether you're spending time on the trails or just working in your backyard, it's worth knowing how to prevent tick bites, recognize early symptoms and get treatment if needed. A little awareness can go a long way in keeping you and your loved ones safe this summer.
What is Lyme disease?
You can get Lyme disease when a tick bites you, spreading a specific type of bacteria.
Dr. Bobbi Pritt, a pathologist who specializes in the laboratory diagnosis of vector-borne and parasitic diseases, explains the disease more in-depth: "Lyme disease is a bacterial infection spread to humans through the bite of infected blacklegged (deer) ticks. In the United States, it is caused primarily by Borrelia burgdorferi, and to a lesser extent, Borrelia mayonii. Lyme disease is the number-one cause of tick-transmitted disease in the United States."
However, the tick has to carry the bacteria to give you Lyme disease. Not all ticks carry the bacteria. According to the Global Lyme Alliance, anywhere from under 1% to over 50% of black-legged ticks may carry Borrelia burgdorferi, depending on location. However, they may have other pathogens.
Dr. Donald Harker, wilderness medicine fellow at the University of Nevada, Reno, says, "Borrelia burgdorferi is a bacterial spirochete that lives in the midgut of infected ticks, typically requiring extended attachment of a tick to host for transmission to occur."
Lyme disease symptoms
"There are three stages of disease including early localized, early disseminated and late disseminated Lyme disease," says Harker.
Stage 1 Lyme disease symptoms
The Mayo Clinic lists symptoms of the early stage occurring three to 30 days after an infected tick has bitten you.
Pritt says the early localized state can include "fever, fatigue, headache, muscle and joint pains and a characteristic 'bull's-eye' rash (known as erythema migrans) at the tick bite site. The rash is seen in about 70% of infected people, but it may go unnoticed, especially if it is on a part of the body that isn't easily seen, such as the scalp or back. The rash enlarges over time and sometimes clears to create the classic target or 'bull's-eye' appearance."
Dr. Omar Al-Heeti, an assistant professor of medicine at Southern Illinois University who practices internal medicine with a specialty in infectious diseases, and one of CNET's medical reviewers, adds, "More common than not, there is not central clearing or 'target' appearance. The rash should be larger than 5 cm."
Willowpix/Getty Images
Stage 2 Lyme disease symptoms
Stage 2 of Lyme disease tends to happen three to 10 weeks after the tick bite.
During stage 2, symptoms can already become serious or deadly. According to Harker, "During transition to early disseminated disease, multiple erythema migrans rashes may develop more distant from the original bite location, along with flu-like symptoms, cranial nerve palsy, meningitis or cardiac conduction abnormalities. While Lyme carditis [occurs when Lyme disease bacteria enter the heart's tissue] is rare, it is a significant cause of Lyme disease-related mortality and has been documented to result in complete heart block in as little as four days after infection."
The Mayo Clinic lists additional symptoms like neck pain and stiffness, painful swelling around the eye or eyelid, eye nerve pain or vision loss, muscle weakness that can happen on one or both sides of the face and body pain.
Stage 3 Lyme disease symptoms
Symptoms from earlier stages can persist into stage 3. But a host of new serious symptoms might arise, characterized most commonly by arthritis in large joints.
"The last stage, late disseminated Lyme disease, presents months to years after the initial tick bite," Harker says. "Characteristic symptoms of late disseminated Lyme disease include Lyme arthritis with pain in one or more major joints and nervous system involvement including sleep disturbance, memory loss, mood swings, migraine, encephalopathy [a change in how your brain functions], vertiginous dizziness and peripheral paresthesia [the sensation of tingling, prickling or numbness]."
Post-Treatment Lyme disease syndrome symptoms
"Some people experience fatigue, joint pain and brain fog lasting six months or more – this is called Post-Treatment Lyme Disease Syndrome (PTLDS), and it can be very debilitating for some people," Pritt states.
No one quite knows why symptoms may persist after treatment. According to Harker, "The etiology of PTLDS is unclear, though several mechanisms have been proposed, including microbial persistence, though no evidence has shown continued infection. Other proposed mechanisms include immune dysregulation, autoimmunity, residual inflammation or gut microbiome alterations, though further research is required at this point."Lyme disease risk factors
Since ticks transmit Lyme disease, it primarily affects people who spend the most time outside in certain regions. Pritt identifies the following risk factors: "Living or spending time in wooded or grassy areas, especially in the Northeast, upper Midwest and Pacific Northwest US, and not using protection against tick bites when outdoors."
Harker mentions other risk factors: "Seasonally, the risk of infection is highest during late spring, summer and early fall when nymphal ticks are most active, though climate changes have enabled tick expansion to regions that have historically not experienced as much tick-borne illness. House pets are also able to bring ticks into the home, with the largest risk associated with cats. Lastly, we do see an increased incidence of infection in certain age groups, including children less than 15 and individuals aged 50-70 years old."
How is Lyme disease diagnosed?
Pritt outlines the whole diagnostic process: "Lyme disease is usually diagnosed through a review of the patient's symptoms in conjunction with a history of tick exposure, and blood tests to detect the patient's immune response to the bacteria (called serologic testing). When present, the bull's-eye rash is considered diagnostic of Lyme disease in endemic areas and should prompt immediate treatment. However, not all cases of Lyme disease are straightforward, and laboratory testing can play a crucial role in making the diagnosis, particularly in the later stages of disease."
How is Lyme disease treated? Can it be cured?
Pritt states that doctors treat with antibiotic courses like doxycycline. Harker adds that treatment may vary based on how someone's symptoms manifest, which organs are infected and what stage of infection the person is experiencing. Oral antibiotics tend to go to those who exhibit rashes. People with more serious symptoms like neurologic issues or heart problems might get IV antibiotics. People with a tick bite and potential exposure may get prophylactic postexposure antibiotics if it is noted that the tick is the deer tick, the bite occurred in a highly endemic area and the tick was attached for over 36 hours.
Treatments can get even more involved for the worst complications. According to Harker, "[For] cardiac manifestations, IV antibiotics [may be used], with a potential need for a pacemaker if [there is the] presence of a symptomatic heart block."
Pritt adds, "Lingering after-treatment symptoms can be very troublesome and challenging to treat. Rest, physical therapy, stress management and support from healthcare providers can help manage symptoms." She adds that lingering symptoms might result from an overactive immune response or residual tissue damage, rather than ongoing infection.
Al-Heeti adds, "Long-term antibiotics are not recommended for PTLDS or chronic Lyme as sometimes prescribed."
rbkomar/Getty Images
What to do if a tick bites you
Follow these steps if you notice that a tick has bitten you:
Remove the tick immediately. "Mechanical removal is generally recommended by experts, and the CDC has endorsed removal with forceps [or tweezers]. During removal, forceps should be placed as close to the skin as possible and force should be applied steadily perpendicular to the skin surface, without twisting and with care used not to crush the tick," says Harker.
"Mechanical removal is generally recommended by experts, and the CDC has endorsed removal with forceps [or tweezers]. During removal, forceps should be placed as close to the skin as possible and force should be applied steadily perpendicular to the skin surface, without twisting and with care used not to crush the tick," says Harker. Clean the area. The CDC says rubbing alcohol or soap and water is OK. Also, make sure to clean both your hands and the bite area.
The CDC says rubbing alcohol or soap and water is OK. Also, make sure to clean both your hands and the bite area. Safely save the tick. "Save the tick, if possible, for identification," recommends Pritt. The CDC advises that you dispose of the tick by "putting it in alcohol, placing it in a sealed bag or container, wrapping it tightly in tape or flushing it down the toilet." Do not crush it with your fingers.
"Save the tick, if possible, for identification," recommends Pritt. The CDC advises that you dispose of the tick by "putting it in alcohol, placing it in a sealed bag or container, wrapping it tightly in tape or flushing it down the toilet." Do not crush it with your fingers. Watch for symptoms and keep in touch with your doctor. Keep an eye out for telltale symptoms like the bull's-eye rash. If exposure is likely and you live in the Northeast, you might consider getting preventative antibiotics from a doctor.
How to prevent Lyme disease
There are currently no Lyme disease vaccines on the market. "A new vaccine is in development and could become available in the next few years, pending approval," says Pritt. There are some in human trials at the moment, says Harker.
Since Lyme disease can range from asymptomatic to deadly, it's best to avoid ticks in the first place using a few easy preventative measures.
Use tick repellent
Harker recommends tick repellants like DEET or picaridin. He also suggests finding tick-resistant clothing treated with permethrin.
Dress appropriately outdoors
Pritt recommends wearing long sleeves and pants when outdoors. Harker reminds us that you can tuck clothing into the waist of pants and socks to minimize gaps that pests can get into.
"Light-colored clothing may also aid in the early identification of ticks attached to clothing," says Harker.
Perform tick checks
"As transmission of the bacteria that causes Lyme disease typically requires a tick to be attached for 15 to 48 hours, frequent skin checks for possible tick exposure should be performed when in outdoor areas with risk of contact," Harker says.
You should also perform frequent tick checks while outside and after. "Showering after being in tick-prone areas can help to identify ticks on your body," says Pritt. "Be sure to check all of the members of your group, including your pets."
When to contact a doctor
Pritt takes a pragmatic approach: "If you develop a rash, fever or flu-like symptoms within 30 days, or if the tick was attached for more than 24 hours, then you should contact your doctor to see if you should be tested for tick-borne diseases."
Harker also says you should contact your doctor if there is any concern, as he states that "prophylactic antibiotics may be indicated and are best administered within the first 72 hours after the tick bite."
The bottom line
Lyme disease is caused by bacteria that live in the deer tick. People contract the disease after the tick has bitten them and been on their bodies for most of the day or longer. Symptoms go in three stages and may start with the signature bull's-eye rash. Later stages can mean arthritis, heart problems, stiffness and pain in the body, eye pain or vision loss and muscle weakness.
It's best to prevent tick bites by covering as much skin as possible outdoors, with regular tick checks and by using tick repellant.
Lyme disease FAQs
Can Lyme disease go away on its own?
According to Cedars Sinai, if untreated, the Lyme infection may go away on its own. However, if untreated, you may have to deal with complications down the line. Watch out for symptoms and contact your doctor if there are any concerns.
Can you live long with Lyme disease?
Yes, you can live a long life even if you contract Lyme disease – especially if it is diagnosed and treated early. Brown University Health reports that it is very unlikely for someone to die from Lyme disease.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Yahoo

time8 minutes ago

  • Yahoo

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (''2510') anticipated before the end of 2025 Updated '2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco DALLAS, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ('Instil') (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2025 financial results and provided a corporate update. Recent Highlights: In June, announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer In July, announced the Investigational New Drug (IND) application for '2510 was cleared by the U.S. FDA In July, ImmuneOnco, Instil's collaborator, announced preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of '2510 in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC) conducted in China by ImmuneOnco In August, ImmuneOnco announced that an abstract has been accepted for poster presentation at IASLC's 2025 World Conference on Lung Cancer (September 6th-9th, 2025), which will provide updated results from additional patients with relapsed/refractory squamous-NSCLC treated with '2510 as monotherapy Second Quarter 2025 Financial and Operating Results: As of June 30, 2025, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $103.6 million, which consisted of $7.7 million in cash and cash equivalents, approximately $0.2 million in restricted cash, $84.1 million in marketable securities, and $11.7 million in long-term investments, compared to $115.1 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2024, consisting of $8.8 million in cash and cash equivalents, $1.8 million in restricted cash, and $104.5 million in marketable securities. Instil expects that its cash, cash equivalents, marketable securities and long-term investments as of June 30, 2025 will enable it to fund its operating plan beyond 2026. In-process research and development expenses were $10.0 million for both the three and six months ended June 30, 2025, compared to nil for both the three and six months ended June 30, 2024. Research and development expenses were $6.7 million and $12.1 million for the three and six months ended June 30, 2025, respectively, compared to $2.9 million and $10.2 million for the three and six months ended June 30, 2024, respectively. General and administrative expenses were $6.2 million and $15.3 million for the three and six months ended June 30, 2025, respectively, compared to $10.7 million and $23.1 million for the three and six months ended June 30, 2024, respectively. Restructuring and impairment charges were $0.5 million and $16.6 million for the three and six months ended June 30, 2025, respectively, compared to $0.5 million and $4.8 million for three and six months ended June 30, 2024, respectively. Net loss per share, basic and diluted were $3.24 and $7.55 for the three and six months ended June 30, 2025, respectively, compared to $2.29 and $6.03 for the three and six months ended June 30, 2024, respectively. Non-GAAP net loss per share, basic and diluted, were $2.88 and $4.21 for the three and six months ended June 30, 2025, respectively, compared to $1.57 and $3.95 for the three and six months ended June 30, 2024, respectively. Note Regarding Use of Non-GAAP Financial Measures In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles ('GAAP'). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil's financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil's operating results. In addition, these non-GAAP financial measures are among the indicators Instil's management uses for planning purposes and to measure Instil's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures. About Instil Bio Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. For more information visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'expects,' 'exploring,' 'future,' 'intends,' 'may,' 'plans,' 'potential,' 'projects,' 'targets' and 'will' or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements regarding our expectations with respect to the therapeutic potential of AXN-2510/IMM2510, clinical development of AXN-2510/IMM2510, including the initiation of clinical trials for AXN-2510/IMM2510 and the generation and presentation of clinical data for AXN-2510/IMM2510 and the timing thereof; research, development, regulatory and clinical plans for AXN-2510/IMM2510; Instil's expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties associated with the costly and time-consuming drug product development process and the uncertainty of clinical success; the risks inherent in relying on collaborators and other third parties, including for manufacturing and generating clinical data, and the ability to rely on any such data from clinical trials in China in regulatory filings submitted to regulatory authorities outside of China; the risks and uncertainties related to successfully making regulatory submissions and initiating, enrolling, completing and reporting data from clinical trials, particularly collaborator-led clinical trials, as well as the risks that results obtained in any clinical trials to date may not be indicative of results obtained in ongoing or future trials and that product candidates may otherwise not be effective treatments in their planned indications; risks related to macroeconomic conditions, including as a result of international conflicts and U.S.-China trade and political tensions, as well as interest rates, inflation, tariffs and other factors, which could materially and adversely affect our business and operations and those of our collaborators; the risks and uncertainties associated with the time-consuming and uncertain regulatory approval process and the sufficiency of Instil's cash resources; and other risks and uncertainties affecting Instil's plans and development programs, including those discussed in the section titled 'Risk Factors' in Instil's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 to be filed with the SEC, as well as Instil's other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law. Contacts: Investor Relations:1-972-499-3350 investorrelations@ INSTIL BIO, FINANCIAL DATA (Unaudited; in thousands, except share and per share amounts) Selected Condensed Consolidated Balance Sheet Data June 30, 2025 December 31, 2024 Cash, cash equivalents, restricted cash, marketablesecurities and long-term investments $ 103,632 $ 115,145 Total assets $ 230,986 $ 263,567 Total liabilities $ 99,316 $ 94,131 Total stockholders' equity $ 131,670 $ 169,436 Condensed Consolidated Statements of Operations Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Operating expenses: In-process research and development $ 10,000 $ — $ 10,000 $ — Research and development 6,743 2,921 12,114 10,177 General and administrative 6,157 10,706 15,266 23,130 Restructuring and impairment charges 540 508 16,622 4,783 Total operating expenses 23,440 14,135 54,002 38,090 Loss from operations (23,440 ) (14,135 ) (54,002 ) (38,090 ) Interest income 1,044 1,919 2,219 3,981 Interest expense (1,582 ) (1,999 ) (2,680 ) (3,980 ) Other rental income 2,242 — 4,484 — Other income (expense), net 342 (702 ) 385 (1,130 ) Net loss $ (21,394 ) $ (14,917 ) $ (49,594 ) $ (39,219 ) Net loss per share, basic and diluted $ (3.24 ) $ (2.29 ) $ (7.55 ) $ (6.03 ) Weighted-average shares used incomputing net loss per share, basic anddiluted 6,596,975 6,503,913 6,564,994 6,503,913 INSTIL BIO, of GAAP to Non-GAAP Net Loss and Net Loss per Share (Unaudited; in thousands, except share and per share amounts) Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Net loss $ (21,394 ) $ (14,917 ) $ (49,594 ) $ (39,219 ) Adjustments: Non-cash stock-based compensationexpense 1,824 4,173 5,319 8,688 Restructuring and impairmentcharges 540 508 16,622 4,783 Non-GAAP net loss $ (19,030 ) $ (10,236 ) $ (27,653 ) $ (25,748 ) Net loss per share, basic and diluted $ (3.24 ) $ (2.29 ) $ (7.55 ) $ (6.03 ) Adjustments: Non-cash stock-based compensationexpense per share 0.28 0.64 0.81 1.34 Restructuring and impairmentcharges per share 0.08 0.08 2.53 0.74 Non-GAAP net loss per share, basicand diluted* $ (2.88 ) $ (1.57 ) $ (4.21 ) $ (3.95 ) Weighted-average shares outstanding,basic and diluted 6,596,975 6,503,913 6,564,994 6,503,913 * Non-GAAP net loss per share, basic and diluted may not total due to in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

How good are the school lunches in Rhode Island? Pretty good, report says. See ranking
How good are the school lunches in Rhode Island? Pretty good, report says. See ranking

Yahoo

time38 minutes ago

  • Yahoo

How good are the school lunches in Rhode Island? Pretty good, report says. See ranking

School in Rhode Island will be starting soon, which means another year of school lunches. As a parent, you're not exactly there with your children to assess the cafeteria food's quality, but you would hope the school lunches are at least healthy and nutritious for the kids there. It would be nice to know for sure, though. In Rhode Island, a recent report found the odds of your child having a healthy lunch are pretty good. ProCare Therapy released the State of School Lunch Report, ranking which states in the U.S. have the healthiest school lunches and which states are lacking in that department, and ranked Rhode Island No. 8 in the U.S. The report took into account participation in the Farm to School program, which includes activities for school gardens and farms so that children can learn about where their food comes from, and other programs. How healthy are Rhode Island school meals With a score of 62.38, Rhode Island was ranked No. 8 out of the 50 states and Washington, D.C., included in the report's list. With this ranking, the Ocean State is one of the most dedicated places in the country toward providing healthy school meals to children, the report said. Vermont took the top spot. "Hawaii also leads in the percentage of schools serving local foods, with Virginia, Washington D.C., Rhode Island, and Oregon following suit, where over 87% of schools provide locally grown food to their students," the report said. The top 10 places in the U.S. for healthiest school meals in the report are: Vermont Hawaii Washington, D.C. West Virginia Delaware Virginia Oregon Rhode Island New York Alaska More: Are the feds coming for coffee milk in schools? They might not even find it on the menu. Here's what you need to know about free lunches in Rhode Island. Are school lunches free in Rhode Island You can apply for free or reduced-price school lunches for your children in Rhode Island, according to the state government website. "The cost of breakfast and lunch varies by school, but regardless of the cost, your children may qualify for free meals or for reduced-price meals," the website said. Rin Velasco is a trending reporter. She can be reached at rvelasco@ This article originally appeared on The Providence Journal: RI ranks No. 8 in healthy school lunches in the U.S., report says Solve the daily Crossword

Being Stalked May Threaten Heart Health in Women
Being Stalked May Threaten Heart Health in Women

Medscape

timean hour ago

  • Medscape

Being Stalked May Threaten Heart Health in Women

TOPLINE: Women who experienced stalking faced a significantly elevated risk for incident cardiovascular disease. While obtaining a restraining order can sometimes limit violence, even the issuance of such rulings — reflecting a history and severity of abuse — may have long-term consequences for cardiovascular health. METHODOLOGY: Researchers analyzed data from more than 66,000 female nurses in the United States (mean age at the start of follow-up, 46.3 years) who reported whether they had ever been stalked or obtained a restraining order. Incident cardiovascular disease, defined as self-reported fatal or nonfatal myocardial infarction or stroke, was tracked over a median follow-up of 19.9 years. In a secondary analysis, medical records were reviewed to confirm or corroborate self-reported cardiovascular events, with approximately 53% of cases adjudicated. Analyses were adjusted for several potential factors including sociodemographic characteristics, family and childhood factors, and health behaviors and conditions in adulthood. TAKEAWAY: Overall, 11.7% of women reported experiencing stalking, and 5.6% reported obtaining a restraining order. During follow-up, 2.8% of women reported developing cardiovascular disease, with 1.5% of cases confirmed through a review of medical records. Women who reported experiencing stalking had a 41% higher risk for self-reported incidence of cardiovascular disease than those who did not (adjusted hazard ratio [aHR], 1.41; 95% CI, 1.24-1.60); those who obtained a restraining order had a 70% higher risk than those who did not (aHR, 1.70; 95% CI, 1.44-1.98). Analyses of adjudicated cardiovascular events showed similarly elevated risks among women with a history of stalking or of obtaining a restraining order. IN PRACTICE: 'Through obtaining a restraining order, women who have experienced violence are identified by agencies; this interaction provides an opportunity to support these women and possibly intervene to limit potential long-term cardiovascular health consequences,' the researchers reported. 'Attempts to understand women's lives beyond traditional risk factors when evaluating [cardiovascular disease] risk likely warrants further attention for health care,' they added. SOURCE: This study was led by Rebecca B. Lawn, PhD, of Harvard T.H. Chan School of Public Health, Boston. It was published online on August 11, 2025, in Circulation. LIMITATIONS: The exposures to violence were self-reported and assessed retrospectively, potentially introducing recall bias and misclassification. The assessment lacked details about the timing of violence. The participants were drawn from an occupational cohort of registered nurses, limiting generalizability. DISCLOSURES: This study received support from the National Institutes of Health, National Institute of Mental Health, National Institute on Aging, and the Broad Trauma Initiative at the Broad Institute of MIT and Harvard. One author reported serving as a paid consultant for the US Department of Justice and Covington and Burling, LLP, and receiving royalties from Guilford Press and Oxford University Press. Another author reported serving on the medical advisory board of several pharmaceutical and healthcare companies and as a past consultant for Happify Health. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store